ANI Pharmaceuticals, Inc. $ANIP Shares Sold by American Century Companies Inc.

American Century Companies Inc. lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 57.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,837 shares of the specialty pharmaceutical company’s stock after selling 34,411 shares during the quarter. American Century Companies Inc. owned about 0.12% of ANI Pharmaceuticals worth $1,730,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ANIP. Envestnet Asset Management Inc. grew its holdings in shares of ANI Pharmaceuticals by 34.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 4,930 shares of the specialty pharmaceutical company’s stock worth $273,000 after buying an additional 1,256 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 4.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company’s stock worth $37,906,000 after buying an additional 30,420 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of ANI Pharmaceuticals by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company’s stock worth $630,000 after buying an additional 675 shares during the last quarter. Stifel Financial Corp grew its holdings in shares of ANI Pharmaceuticals by 20.4% during the fourth quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company’s stock worth $466,000 after buying an additional 1,425 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of ANI Pharmaceuticals by 20.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,288 shares of the specialty pharmaceutical company’s stock worth $403,000 after buying an additional 1,220 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In other news, Director Jeanne Thoma sold 21,540 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $89.15, for a total transaction of $1,920,291.00. Following the completion of the sale, the director directly owned 23,405 shares in the company, valued at approximately $2,086,555.75. This trade represents a 47.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Antonio R. Pera sold 5,421 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $89.73, for a total transaction of $486,426.33. Following the sale, the director owned 29,952 shares of the company’s stock, valued at approximately $2,687,592.96. The trade was a 15.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 405,538 shares of company stock worth $35,690,131. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $93.50 on Tuesday. The firm has a 50 day moving average of $73.93 and a 200-day moving average of $67.36. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $93.72. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The company has a market cap of $2.03 billion, a price-to-earnings ratio of -121.43 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same period last year, the firm earned $1.02 EPS. The company’s revenue for the quarter was up 53.2% on a year-over-year basis. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ANIP shares. Guggenheim reissued a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $93.00 price objective (up previously from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $84.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.